Endologix, Inc. is singularly focused on providing innovative, minimally invasive technologies for aortic disorders. The Company's product offering includes a variety of endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. Designed around key issues with challenging anatomies, difficult access, and aneurysm sealing, Endologix products have been clinically proven in delivering positive patient outcomes. 

Type
Public
HQ
Irvine, US
Founded
1992
Size (employees)
782 (est)
Endologix was founded in 1992 and is headquartered in Irvine, US
Report incorrect company information

Key People/Management at Endologix

John McDermott

John McDermott

Chief Executive Officer and Director
Vaseem Mahboob

Vaseem Mahboob

Chief Financial Officer
Michael Chobotov

Michael Chobotov

Chief Technology Officer
John Onopchenko

John Onopchenko

Chief Operating Officer
Dan Lemaitre

Dan Lemaitre

Chairman of the Board
Matthew Thompson

Matthew Thompson

Chief Medical Officer
Show more

Endologix Office Locations

Endologix has offices in Rosmalen and Irvine
Irvine, US (HQ)
2 Musick
Rosmalen, NL
40 Burgemeester Burgerslaan
Show all (2)
Report incorrect company information

Endologix Financials and Metrics

Endologix Financials

Endologix's revenue was reported to be $192.93 m in FY, 2016 which is a 25.6% increase from the previous period.
USD

Revenue (Q2, 2017)

48.6 m

Gross profit (Q2, 2017)

32.2 m

Gross profit margin (Q2, 2017), %

66.4%

Net income (Q2, 2017)

(16.3 m)

EBIT (Q2, 2017)

(7.9 m)

Market capitalization (25-Apr-2018)

351.1 m

Cash (30-Jun-2017)

81.6 m
Endologix's current market capitalization is $351.1 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

132.3 m147.6 m153.6 m192.9 m

Revenue growth, %

12%4%26%

Cost of goods sold

41.8 m51.8 m69.1 m

Gross profit

105.8 m101.8 m123.8 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

33.3 m33.3 m38.3 m37.2 m36.7 m39.5 m38.2 m42.4 m51 m52.1 m42.6 m48.6 m

Cost of goods sold

7.4 m9 m9.8 m13.6 m9.8 m15.3 m11.2 m14.4 m21.5 m15.2 m14 m16.3 m

Gross profit

25.9 m24.3 m28.5 m23.6 m26.9 m24.1 m27 m27.9 m29.5 m36.9 m28.6 m32.2 m

Gross profit Margin, %

78%73%74%63%73%61%71%66%58%71%67%66%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

95.2 m26.8 m124.6 m26.1 m

Accounts Receivable

310 k498 k375 k1.8 m

Inventories

19.6 m31.3 m27.9 m41.2 m

Current Assets

173.6 m147.8 m237.5 m129.8 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

49.5 m42.2 m31.8 m27.5 m20.2 m36.3 m35.4 m39.8 m31.4 m22 m15.5 m81.6 m

Accounts Receivable

312 k690 k910 k878 k448 k121 k304 k2.6 m825 k659 k952 k390 k

Inventories

18 m24 m28.5 m27.7 m35.1 m30.6 m33.4 m43.3 m42.1 m43.4 m42.7 m43.6 m

Current Assets

93.4 m172.3 m170.7 m158.4 m138.4 m133 m132.3 m172.3 m155.3 m148.5 m113 m175.8 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(32.4 m)(50.4 m)(154.7 m)

Depreciation and Amortization

3.3 m5.9 m9.1 m

Inventories

(12 m)3.5 m3.5 m

Accounts Payable

2.7 m8.3 m(5.2 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(9 m)5.3 m(9 m)(13.9 m)(11.2 m)(13 m)(10.9 m)(47.7 m)(66.8 m)(15.2 m)(21.3 m)

Inventories

28.5 m27.7 m35.1 m30.6 m33.4 m43.3 m42.1 m43.4 m42.7 m

Accounts Payable

11.5 m10.8 m11.1 m11.8 m13.8 m15.7 m13.8 m13 m9.6 m
USDY, 2017

Financial Leverage

4.2 x
Show all financial metrics
Report incorrect company information